Get the Stockscreener App
21.45
1.29%
-0.28
After Hours:
21.45
Pacira Biosciences Inc stock is traded at $21.45, with a volume of 741.75K.
It is down -1.29% in the last 24 hours and down -6.45% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$21.73
Open:
$21.8
24h Volume:
741.75K
Relative Volume:
0.87
Market Cap:
$881.60M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
14.79
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+5.35%
1M Performance:
-6.45%
6M Performance:
-13.54%
1Y Performance:
-20.94%
1-Day Range:
$21.29
$22.09
1-Week Range:
$20.43
$22.09
52-Week Range:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.45 | 893.10M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.37 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.64 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.13 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 - GlobeNewswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Pacira BioSciences Highlights Positive Impact of NOPAIN Act on Non-Opioid Pain Management in New Survey Findings - Quiver Quantitative
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
2026-02-08 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
NJ Judges Tosses Pacira Investor Suit Over Patent Loss - Law360
2026-02-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out | NDAQ:PCRX | Press Release - Stockhouse
Avoiding Lag: Real-Time Signals in (PCRX) Movement - Stock Traders Daily
Pacira BioSciences (PCRX) Stock Price, News & Analysis - MarketBeat
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com - Investing.com Nigeria
Pacira BioSciences SVP Lauren Riker sells $83k in stock - Investing.com
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares - MarketBeat
Pacira BioSciences officer Williams sells $269k in shares By Investing.com - Investing.com Canada
Pacira BioSciences officer Williams sells $269k in shares - Investing.com
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
2026-02-01 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
In A Strategic Move, Samit Hirawat Acquires Pacira BioSciences Stock Options Worth $9K: Enhancing Value - Benzinga
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Gap Down: What is Deluxe Corporations valuation compared to sectorQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com - Investing.com Nigeria
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Pacira BioSciences Inc.’s technical support levels2025 Sector Review & Technical Buy Zone Confirmations - mfd.ru
Pacira appoints Samit Hirawat to board of directors - TipRanks
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Pacira BioSciences appoints Samit Hirawat to board of directors - Investing.com
Bristol Myers drug development leader joins Pacira board - Stock Titan
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unveiling a 44.95% Potential Upside for Investors - DirectorsTalk Interviews
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. stock deliver shareholder valueDebt-to-Equity Ratio Analysis & Smarter Trades Backed by Machine Learning - bollywoodhelpline.com
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途牛牛
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
10.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):